Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers (Q34682521)

3 August 2017

title

Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers (English)

1 reference

3 August 2017

0 references

1 reference

Bruno Dubois

0 references

Corinna Porteri

object named as

Corinna Porteri

1 reference

3 August 2017

Karl-Olof Lovblad

1 reference

Panteleimon Giannakopoulos

3 August 2017

object named as

Panteleimon Giannakopoulos

1 reference

3 August 2017

Anton Gietl

0 references

Valentina Gallo

0 references

Jean-Francois Démonet

object named as

Jean-Francois Démonet

0 references

Oskar Hansson

0 references

Flavio Nobili

0 references

Philip Scheltens

1 reference

3 August 2017

Ida Sonni

0 references

Kaj Blennow

1 reference

3 August 2017

Stefan Teipel

1 reference

3 August 2017

Paolo Vineis

1 reference

3 August 2017

Bengt Winblad

1 reference

3 August 2017

Frederik Barkhof

1 reference

3 August 2017

Maria C Carrillo

1 reference

3 August 2017

Clifford R Jack

1 reference

3 August 2017

Agneta Nordberg

1 reference

3 August 2017

Niklas Mattsson

1 reference

3 August 2017

Emiliano Albanese

1 reference

3 August 2017

Patrick Bossuyt

1 reference

3 August 2017

José-Luis Molinuevo

2 references

ORCID Public Data File 2021

3 August 2017

Giovanni B Frisoni

1 reference

3 August 2017

Jonathan M Schott

1 reference

3 August 2017

Pieter Jelle Visser

1 reference

3 August 2017

Mara Ten Kate

1 reference

3 August 2017

Karl Herholz

1 reference

3 August 2017

Stefano Cappa

1 reference

3 August 2017

Heather M Snyder

1 reference

3 August 2017

Agnese Picco

1 reference

3 August 2017

Ezio Giacobini

1 reference

3 August 2017

Alessandro Padovani

1 reference

3 August 2017

Marina Boccardi

1 reference

3 August 2017

Konstantinos Chiotis

1 reference

3 August 2017

Valentina Garibotto

1 reference

3 August 2017

Andrea Varrone

1 reference

3 August 2017

Stefanie Becker

1 reference

3 August 2017

Chiara Cerami

1 reference

3 August 2017

Gabriel Gold

1 reference

3 August 2017

Samia Hurst

1 reference

3 August 2017

Anders Lönneborg

1 reference

3 August 2017

Andreas U Monsch

1 reference

3 August 2017

Urs Mosimann

1 reference

3 August 2017

Osman Ratib

1 reference

3 August 2017

Laure Saint-Aubert

1 reference

3 August 2017

Charles Scerri

1 reference

3 August 2017

Yutaka Yasui

1 reference

3 August 2017

publication date

11 July 2017

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

661-676

1 reference

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Relation of neuropathology to cognition in persons without cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Amyloid plaque core protein in Alzheimer disease and Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Neocortical cell counts in normal human adult aging

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Mild cognitive impairment: clinical characterization and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Current concepts in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Diagnostic impact of [18F]flutemetamol PET in early-onset dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Home-brew tests need regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

MR-based in vivo hippocampal volumetrics: 1. Review of methodologies currently employed.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Characterizing Alzheimer's disease using a hypometabolic convergence index

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Fully-automated quantification of regional brain volumes for improved detection of focal atrophy in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Supporting evidence for using biomarkers in the diagnosis of MCI due to AD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Biomarker validation and testing

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Imaging markers for Alzheimer disease: which vs how

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Hippocampus and Basal Forebrain Volumetry for Dementia and Mild Cognitive Impairment Diagnosis: Could It Be Useful in Primary Care?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Diagnosis: The Italian Selfie.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Visual versus semi-quantitative analysis of 18F-FDG-PET in amnestic MCI: an European Alzheimer's Disease Consortium (EADC) project

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Prescription and choice of diagnostic imaging by physician specialty in Alzheimer's Centers (Unità di Valutazione Alzheimer - UVA) in Northern Italy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Amyloid biomarkers in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Reply: Do we still need positron emission tomography for early Alzheimer's disease diagnosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

1 reference

7 January 2021

The biomarker-based diagnosis of Alzheimer's disease. 1-ethical and societal issues

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Rates of formal diagnosis in people screened positive for dementia in primary care: results of the DelpHi-Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Phases of biomarker development for early detection of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

The biomarker-based diagnosis of Alzheimer's disease. 2-lessons from oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Clinical validity of presynaptic dopaminergic imaging with 123I-ioflupane and noradrenergic imaging with 123I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase develop

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

An autoradiographic evaluation of AV-1451 Tau PET in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

PET Quantification of Tau Pathology in Human Brain with 11C-PBB3.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Tau PET in Alzheimer disease and mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Tau positron emission tomographic imaging in aging and early Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Evidence-based indications for the use of PET-CT in the United Kingdom 2016.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

EFNS task force: the use of neuroimaging in the diagnosis of dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Tau imaging in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

The clinical value of fluid biomarkers for dementia diagnosis - Authors' reply

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Quantitative imaging biomarkers: the application of advanced image processing and analysis to clinical and preclinical decision making

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Defeating Alzheimer's disease and other dementias: a priority for European science and society

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Cholinesterase inhibitor use in Alzheimer's disease: the EPIFARM-Elderly Project.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2817%2930159-X

7 January 2021

10.1016/S1474-4422(17)30159-X

Identifiers

DOI

1 reference

3 August 2017

1 reference